Trial · NCT03973268
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
NCT03973268, Phase 1, Recruiting, National Institute of Mental Health (NIMH)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression. Trials, record NCT03973268. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03973268
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
- NCT number
- NCT03973268
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 70 participants, estimated
- Lead sponsor
- National Institute of Mental Health (NIMH)
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Interventions
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions
- First posted
- 2019-06-04
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acute Antidepressant Efficacy: Change from baseline Montgomery Asberg Depression Rating Scale (MADRS) score post ketamine infusion | Baseline, Day 1 | Clinical rating scale of depression |
| Primary | Continued Antidepressant Efficacy: Change from baseline MADRS score post treatment with ketamine with perampanel versus placebo. | Baseline, Day 1, Day 2 Day 7 | Clinical rating scale of depression |
| Secondary | Acute Antidepressant Efficacy: Change in slow wave activity/slope post ketamine infusion | Baseline (night), Day 1 (night) | Polysomnography (PSG)/Electroencephalography (EEG) data |
| Secondary | Acute Antidepressant Efficacy: Change in synaptic plasticity post ketamine infusion | Baseline, Day 1 | Transcranial Magnetic Stimulation (TMS) data |
| Secondary | Continued Antidepressant Efficacy: Gamma power change from baseline post treatment with ketamine with perampanel versus placebo | Baseline, Day 1 | Magnetoencephalography (MEG) data |
| Secondary | Continued Antidepressant Efficacy: Change in slow wave activity/slope from baseline post treatment with ketamine with perampanel versus placebo | Baseline (night), Day 1 (night) | PSG/EEG data |
| Secondary | Continued Antidepressant Efficacy: Change in synaptic plasticity from baseline post treatment with ketamine with perampanel versus placebo | Baseline, Day 1 | TMS data |
| Secondary | Acute Antidepressant Efficacy: Gamma power change from baseline post ketamine infusion | Baseline, Day 1 | Magnetoencephalography (MEG) data |
| Secondary | Acute Antidepressant Efficacy: Change in peripheral measures associated with the administration of ketamine | Baseline, Day 1, Day 2, Day 7 | Plasma/serum biomarkers |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03973268
GET https://conductscience.org/api/trials/v1/NCT03973268/registered